Product Development Partnership on Discovery and Development of Health Technologies

Transcription

1 Product Development Partnership on Discovery and Development of Health Technologies Improving Access to Essential Health Technologies: Focusing on Neglected Diseases, Reaching Neglected Populations Prince Mahidol Award Conference Bangkok, 1 2 Feb 2007 Dr P V Venugopal, Ph D Director (International Operations) MMV, Geneva E mail: venugopalp@mmv.org

2 Millennium Development Goals (Health) Principal MDG Health Targets Reduce by two-thirds, between 1990 and 2015, under-five mortality rate (MDG 5) Reduce by three-quarters, between 1990 and 2015, the maternal mortality ratio (MDG 6) Have halted by 2015 and begun to reverse the spread of HIV/AIDS (MDG 7) Have halted by 2015 and begun to reverse the incidence of malaria and other major diseases (MDG 8) In cooperation with pharmaceutical companies provide access to affordable, essential drugs in developing countries (MDG 17)

3 Data Quoted in WHA % of death due to infectious diseases occur in developing countries 2. Only 13 of 1400 new drugs developed between 1975 and 1999 were for tropical or neglected diseases 3. Insufficient R & D in neglected diseases and poverty related diseases

4 Public-private partnerships POWER OF PARTNERSHIP

5 Power of partnership Public Private North South South South

6 Colaboración Centros Públicos - Centros Privados

7 R&D Initiatives DNDi DNDi DNDi DNDi DNDi DNDi MSF MSF Access Access Campaing Campaing MMV, MMV, MVI MVI GATB GATB Novartis Novartis Singapore Singapore Novartis Novartis Singapore Singapore MSF MSF Access Access Campaing Campaing MSF MSF Access Access Campaing Campaing SCI SCI Glaxo Glaxo R/D R/D Glaxo Glaxo R/D R/D Source: TDR

8 MMV - A Public Private Partnership MMV Launch Nov 3 rd, 1999

9 MMV s Mission: Malaria Drug Innovation for Global Public Good 1. Discover Affordable 2. Develop Anti Malarial Drugs Appropriate Accessible 3. Deliver

10 Value added through effective Public-Private Partnership. MMV Inputs $$$ Drug Profile Partner Management Link to WHO/RBM/Policy Malaria Expertise Evaluation / Monitoring Public Joint MMV Gets Rights in DEC IPR in Field Drug Supply Return on non DEC Sales Industry Inputs Chemistry IPR Toxicology Know How Assets in Kind Technology Liability Insurance R&D For the Public Good Private Industry Gets Rights in non DEC IPR outside Field PR Benefit HR Benefit Validation of Technology

11 A Global Network of Partners in 34 Countries: Academia, Industry and Clinical research centres: Liverpool School of Tropical Medicine University of California, San Francisco University of Liverpool Oxford University University of Washington GlaxoSmithKline LSHTM Immtech International STI GlaxoSmithKline F. Hoffmann-La Roche University of Iowa Novartis Pharma WHO/(TDR) Yale University Sigma-Tau Industrie Farmaceutiche Riunite Albert Einstein College of Medicine GlaxoSmithKline Ranbaxy Laboratories Limited WRAIR Texas A&M Tres Cantos National Institutes of Health (NIH) University of Mississippi University of Nebraska Medical Center University of North Carolina Chapel Hill BIOTEC Mahidol University Korea Shin Poong Pharm. Inc. Holley Pharma University of Buea, Cameroon = Pharmaceutical partner = University/institute = National research institute = Clinical trial site ( = under review) = International agency Everyday, more than 800 scientists, doctors and clinicians are working with MMV on developing new antimalarials Monash University

12 MMV Portfolio 4 th Q 2006 Exploratory Discovery Preclinical Development Regulatory Lead Lead Identification Optimization Phase I Phase II Phase III PSAC antagonists Novel Liver Stage Antimalarials OZ Next Generation OZ + PQP RBx Piperaquine Tablet, Pediatric and Intravenous RBx11160 Chlorproguanil - dapsone (Lapdap ) - artesunate (CDA) Pf enoyl-acp reductase (Fab I) Immucillins New dicationic molecules Enantioselective 8-aminoquinoline NPC1161 AQ-13 New aminoquinoline Pediatric Coartem Cameroonian Medicinal Plants TDR22093 Series 4(1H)- pyridones Back ups Isoquine (an improved aminoquinoline) Dihydroartemisininpiperaquine DHA + PQP Novartis Institute for Tropical Diseases Collaboration Falcipain (cysteine protease) 4(1H)- pyridone GW Pyronaridine Artesunate PYRAMAX Broad Institute of MIT/Harvard Genzyme Collaboration Natural Products Whole-Cell HTS Natural Products as New Prototypes Novel Macrolides Dihydrofolate reductase (DHFR) Dihydroorotate dehydrogenase inhibitors 17 Projects 6 New Projects to be added 3 mini-portfolios Projects in the GSK/MMV mini-portfolio Projects under contract negotiation Projects no longer contract negotiation

13 The Good News: 6 Phase III Development Projects 1. Dihydroartemisinin-piperaquine - Eurartesim 2. Pediatric Artemether-Lumafantrine (Coartem ) 3. Clorproguanil-Dapsone-Artesunate (CDA) 4. Pyronaradine-Artesunate (PYRAMAX ) 5. Mefloquine-Artesunate 6. Amodiaquine-Artesunate Largest number of late stage development anti-malarial drugs in in history! All ACTs in line with WHO guidelines

14 Conclusions Partnerships exploit the talents of the Academia, Public Institutions and Private Industry to the full extend for public good By ensuring effective team work, Industry norms are often exceeded in achieving the milestones in Research, Development and Delivery Partnerships substantially reduce the cost or R & D Innovative management of Intellectual Property can ensure access at affordable prices to all

15 Let us hope that the Millennium Development goals are not just achieved, but exceeded!

16 Thank you